UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 1, 2023, the Board of Directors (the “Board”) of AptarGroup, Inc. (the “Company”) appointed Julie Xing as a director effective as of such date. Ms. Xing will serve as a director for a term expiring at the Company’s 2023 annual meeting of stockholders. The Board has determined that Ms. Xing is an “independent director” under New York Stock Exchange rules and has not yet determined any Board committee on which Ms. Xing will serve.
Ms. Xing, 54, serves as the Executive Chair of the Board of Directors of Mundipharma (China) Pharmaceutical Company Limited, a multinational research-based pharmaceutical company, since 2022, and also serves as Board Advisor on the Board of Directors for Mars, a global manufacturer of confectionery, pet food and provider of animal care services. With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Ms. Xing has developed an in depth knowledge of the pharmaceutical market and the Asian region.
Ms. Xing’s compensation for service on the Board will be consistent with that of other non-employee directors of the Company, as described in the Company’s definitive proxy statement with respect to its 2022 annual meeting of stockholders filed with the Securities and Exchange Commission on March 25, 2022. There are no other arrangements or understandings between Ms. Xing and any other person pursuant to which she was appointed as director, and Ms. Xing is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 1, 2023 | AptarGroup, Inc. | ||
By: | /s/ Kimberly Y. Chainey | ||
Kimberly Y. Chainey | |||
Executive Vice President, Chief Legal Officer and Corporate Secretary |
Cover |
Mar. 01, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Mar. 01, 2023 |
Entity File Number | 1-11846 |
Entity Registrant Name | AptarGroup, Inc. |
Entity Central Index Key | 0000896622 |
Entity Tax Identification Number | 36-3853103 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 265 Exchange Drive |
Entity Address, Address Line Two | Suite 301 |
Entity Address, City or Town | Crystal Lake |
Entity Address, State or Province | IL |
Entity Address, Postal Zip Code | 60014 |
City Area Code | 815 |
Local Phone Number | 477-0424 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $.01 par value |
Trading Symbol | ATR |
Security Exchange Name | NYSE |
Entity Emerging Growth Company | false |
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end
/QT_9SJV
MM!D51,Z$QJY4E?II5##3@R?H4K'X?&P6L)?KLU1 N""